CCDC170

Across TCGA pan-cancer cohorts, CCDC170 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CCDC170 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CCDC170 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC170 expression acts as an unfavorable survival marker, although some lineages such as LUSC and HNSC show a favorable association.

DLBC, ACC, and PRAD are the cancer types where CCDC170 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
PRAD	DFS	Median	All	0.617	0.886	.027	6	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUAD	OS	Median	All	0.348	0.677	.024	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →
LUSC	DFS	Median	All	0.838	0.650	.038	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
HNSC	OS	Median	IV	1.000	0.341	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CCDC170–DLBC (OS)

Open the DLBC breakdown →